GEA Process Engineering Inc. @ InformEx USA 2010, stand 109

Published: 11-Feb-2010 Featured companies: GEA Pharma and Healthcare

GEA Process Engineering is the US supplier of the world-recognised GEA Niro spray dryers. GEA Niro spray dryers for the pharmaceutical industry range from small capacity units designed for r&d to industrial-size plants for continuous production under cGMP conditions.
The offerings to the pharmaceutical industry also include spray drying process development and contract manufacturing at the GEA Niro Pharma Test Station in Copenhagen, Denmark - one of the most advanced cGMP spray drying facilities worldwide. The facility includes two GEA Niro PHARMASD spray dryers; a PSD-1 small-scale unit suitable for initial tests and production of small quantities and a PSD-4 unit for full-scale production.
For more information go to
www.niro.com/PTS

Featured companies

GEA is a leading provider of process technology and packaging solutions for the pharmaceutical, biopharmaceutical, biotechnology and nutraceutical industries. Our portfolio...
See more

You may also like

Manufacturing

Aseptic spray drying: Transforming biotherapeutics for a new era

Read more
With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications

Trending Articles

  1. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research
  2. Touchlight named most innovative new manufacturing facility at ISPE 2025 Facility of the Year Awards The company’s restored Victorian waterworks site in Hampton, London, has been recognised for transforming DNA manufacturing with its enzymatic, cell-free dbDNA platform
  3. Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
  4. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
  5. ACG to invest $200m in US hard-shell capsule manufacturing ACG will build its first US capsule manufacturing facility in Atlanta, Georgia, with dedicated gelatine and HPMC lines, creating more than 200 jobs and expanding its North American presence ahead of operations starting in early 2027

Relevant companies

See more

You may also like

Manufacturing

Aseptic spray drying: Transforming biotherapeutics for a new era

With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Manufacturing

Almac expands bioavailability capabilities to address a critical need in drug development

Almac Group has completed a multimillion-pound expansion of its bioavailability enhancement capabilities at its facility in Charnwood, UK
Manufacturing

Sustainability that performs: how GEA is building a better future for pharma

By embedding ESG principles into pharmaceutical manufacturing, GEA is delivering measurable sustainability performance without compromising compliance or productivity
Manufacturing

GEA raises guidance following strong H1 performance

Revised forecast reflects improved margins, robust order intake and efficiency gains
Manufacturing

First product chambers placed in GEA's "Factory of the Future"

Responding to the growing demand for freeze-drying systems, GEA Pharma & Healthcare is investing €80m in the construction of a pharmaceutical technology centre in Elsdorf (North Rhine-Westphalia)
Manufacturing

A forward-thinking approach to reducing downtime and costs in the pharmaceutical industry

Implementing predictive maintenance and a lifecycle package can significantly reduce both downtime and costs in the pharmaceutical industry, emphasises Benoit Dehaene from GEA Pharma & Healthcare
Subscribe now